Aurobindo Pharma Subsidiary Eugia Pharma Launches Pomalidomide Capsules in US Market

Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has launched Pomalidomide Capsules, 1 mg, 2 mg, 3 mg and 4 mg, in the US market. The product is the generic equivalent of Pomalyst® Capsules, 1 mg, 2 mg, 3 mg and 4 mg, of BMS Pharmaceuticals Corp. Eugia Pharma Specialities Limited was one of the First-to-File (FTF) ANDA applicants for this product. The product will be manufactured at Eugia Unit-I. According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately USS 3.3 billion in the U.S. Pomalidomide is a third-generation immunomodulatory drug (IMiD) used in combination with dexamethasone (and sometimes bortezomib) to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma. Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India, with a robust product portfolio spread over seven major therapeutic/product areas.